Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
Oncotarget|September 2, 2015
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphomaLing Li, Zijun Y Xu-Monette, Chi Young Ok, et al.
Aging|February 17, 2016
p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor functionZijun Y Xu-Monette, Shanxiang Zhang, Xin Li, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphomaTimothy S Fenske, Parameswaran N Hari, Jeanette Carreras, et al.
Blood|March 22, 2013
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium ProgramYong Li, Michael W Gordon, Zijun Y Xu-Monette, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2015
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functionsChi Young Ok, Zijun Y Xu-Monette, Ling Li, et al.
Oncotarget|March 12, 2015
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countriesZijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, et al.
Oncotarget|February 24, 2015
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaJiayu Chen, Zijun Y Xu-Monette, Lijuan Deng, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 23, 2019
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium ProgramLing Li, Ruifang Sun, Yi Miao, et al.
Blood Advances|November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC ConsortiumJohn Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Pageof 26